In summary, since splicing factor‐mutated and MYC‐driven tumours are more sensitive to splicing modulation, CDK11 inhibition could represent a novel synthetically lethal interaction for such splicing‐dependent cancers. This evidence concerns the gene MYC and neoplasm.